My husband traveled to Turkey mid-January to receive Ac-225 after Pluvicto failed. In spite of high PSMA uptake and no discordance, treatment failed as the widespread disease burden was too great. His liver mets in particular has grown exponentially since August when it was first seen immediately prior to first Pluvicto. (He had Pylarify scan plus MRI and CT in July 2022, and no lesions were yet seen in liver.)
His disease has continued to progress since his Ac-225 treatment just 6 weeks ago, and he will receive no further treatments in Turkey. (By the way, he tolerated treatment well with no dry mouth!)
Currently he is weak, having difficulty eating, and his Hgb has been low at 7.5. He has minimal to no discomfort and is not yet ready to give up on treatment. He would love to enjoy a few more months at least.
His Guardant 360 does show a CHEK 2 mutation which would make him eligible for Lynparza. He also has a high TMB of 14.35 which makes him eligible for Keytruda.
He is also willing to try chemo, again, as he has always tolerated it well. We do understand that it could be more difficult due to his current weakened condition.
I turn to this knowledgeable group for suggestions on where to turn next. Would he even be eligible for a clinical trial in his weakened state? Is there any hope for Lynparza or Keytruda giving him a reasonable QOL? Can he take both at the same time? Or should he try chemo?
Any and all input is appreciated. We will travel if necessary, although it’s a bit more challenging than it was.
Tall_Allen, do you think he could still benefit by a consult with Tanya Dorff? Where do you think we should turn?
Thank you in advance, and thank you for all the support, advice, and caring that we have already received from this group.